01:05:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss.
2021-11-30 15:06:16
Moss, 30 November 2021

Reference is made to the annual general meeting 4 May 2021 where a statement of
remuneration to key personnel was given. In accordance with this statement the
board of Gentian Diagnostics ASA has allocated a total of 165,674 options to key
employees under the existing option program.

The following number of options have been allocated to primary insiders of
Gentian Diagnostics ASA:

Njaal Kind, Group Chief Financial Officer: 40,674 options. Following the
allocations Mr. Kind hold 21,125 shares and 155,670 options in the Company.

Erling Sundrehagen, Chief Scientific Officer: 20,000 options. Following the
allocation Mr. Sundrehagen and related parties hold 184,083 shares and 120,000
options in the Company.

Torsten Knüttel, Vice President R&D: 20,000 options. Following the allocation
Mr. Knüttel hold 1,125 shares and 30,000 options in the Company.

Jack Andreassen, Vice President Business Development: 2,500 options. Following
the allocation Mr. Andreassen hold 4,385 shares and 22,500 options in the
Company.

Markus Jaquemar, Vice President Sales and Marketing: 2,500 options. Following
the allocation Mr. Jaquemar holds 22,500 options in the Company.

Attached is the notifications of the transactions pursuant to the market abuse
regulation article 19.

The exercise price for the options granted is NOK 72.60 being the average
volume-weighted share price on the Oslo Stock Exchange for the past 10 trading
days prior to 24 November. The right to exercise the options is vested over a
period of 3 years, with 1/3 of the options vesting by the end of each year as
follows: (i) 1/3 of the options granted, no earlier than 2 years after the
allocation date (ii) 1/3 of the options granted, no earlier than 3 years after
the allocation date (iii) 1/3 of the options granted, no earlier than 4 years
after the allocation date.

For further information, please contact:

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.